Included in the formulation
АТХ:H.05.B.X.04 Ethylcalcytide
Pharmacodynamics:It binds to the parathyroid gland receptors, reducing the secretion of parathyroid hormone, which leads to a decrease in the level of calcium in the blood plasma.
Pharmacokinetics:After intravenous administration, the maximum concentration in the blood plasma is reached after 30 minutes.
The half-life is 18 hours. Elimination by the kidneys.
Indications:It is used for the treatment of secondary hyperparathyroidism in patients with chronic renal failure who are on hemodialysis.
IV.E20-E35.E21.1 Secondary hyperparathyroidism, not elsewhere classified
Contraindications:Age to 18 years, pregnancy and lactation, individual intolerance.
Carefully:Heart failure, arrhythmia.
Pregnancy and lactation:Recommendations for FDA - Category C. Contraindicated in pregnancy and lactation.
Dosing and Administration:Intravenously, after the end of the hemodialysis session, 5 mg 3 times a week. The dose can be reduced to 2.5 mg or increased to 15 mg, depending on the concentration of calcium in the blood plasma.
The highest daily dose: 15 mg.
The highest single dose: 15 mg.
Side effects:Central and peripheral nervous system: headache, paresthesia.
The cardiovascular system: arterial hypotension, lengthening of the interval QT.
Digestive system: nausea, diarrhea, vomiting.
Musculoskeletal system: muscle spasms.
Allergic reactions.
Overdose:Cases of overdose are not described.
Treatment is symptomatic.
Interaction:Clinically significant interactions are not described.
Special instructions:Monitoring of the calcium content in the blood serum.
When taking the drug is not recommended driving and working with moving machinery.